EP1877042A4 - Bioenhanced compositions - Google Patents

Bioenhanced compositions

Info

Publication number
EP1877042A4
EP1877042A4 EP06750455A EP06750455A EP1877042A4 EP 1877042 A4 EP1877042 A4 EP 1877042A4 EP 06750455 A EP06750455 A EP 06750455A EP 06750455 A EP06750455 A EP 06750455A EP 1877042 A4 EP1877042 A4 EP 1877042A4
Authority
EP
European Patent Office
Prior art keywords
bioenhanced
compositions
bioenhanced compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06750455A
Other languages
German (de)
French (fr)
Other versions
EP1877042A2 (en
Inventor
Nagesh R Palepu
Pratibha S Pilgaonkar
Maharukh T Rustomjee
Anilkumar S Gandhi
Paras R Jain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rubicon Research Pvt Ltd
Original Assignee
Rubicon Research Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rubicon Research Pvt Ltd filed Critical Rubicon Research Pvt Ltd
Publication of EP1877042A2 publication Critical patent/EP1877042A2/en
Publication of EP1877042A4 publication Critical patent/EP1877042A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP06750455A 2005-04-18 2006-04-18 Bioenhanced compositions Withdrawn EP1877042A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN477MU2005 2005-04-18
IN315MU2006 2006-03-06
PCT/US2006/014422 WO2006113631A2 (en) 2005-04-18 2006-04-18 Bioenhanced compositions

Publications (2)

Publication Number Publication Date
EP1877042A2 EP1877042A2 (en) 2008-01-16
EP1877042A4 true EP1877042A4 (en) 2011-03-02

Family

ID=37115820

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06750455A Withdrawn EP1877042A4 (en) 2005-04-18 2006-04-18 Bioenhanced compositions

Country Status (8)

Country Link
EP (1) EP1877042A4 (en)
JP (1) JP2008536929A (en)
KR (1) KR20080042039A (en)
AU (1) AU2006236497A1 (en)
CA (1) CA2605183A1 (en)
IL (1) IL186721A0 (en)
MX (1) MX2007012947A (en)
WO (1) WO2006113631A2 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1973531A2 (en) * 2006-01-02 2008-10-01 Rubicon Research Private Limited Pharmaceutical compositions
AU2007293727A1 (en) * 2006-09-05 2008-03-13 Astrazeneca Ab Pharmaceutical composition comprising candesartan cilexetil
EA026213B1 (en) * 2006-10-20 2017-03-31 Солвей Фармасьютикалс Б.В. Thermostable solid pharmaceutical composition comprising nanomicelles and process for preparing same
US7923026B2 (en) 2006-10-20 2011-04-12 Solvay Pharmaceuticals B.V. Embedded micellar nanoparticles
WO2008064338A2 (en) * 2006-11-22 2008-05-29 Rubicon Research Pvt. Ltd. Valsartan formulation for pulsatile delivery
EP2099431B1 (en) * 2006-11-28 2013-06-05 Laboratorios Liconsa, S.A. Stabilized solid pharmaceutical composition of candesartan cilexetil
RU2009125613A (en) * 2006-12-05 2011-01-20 Новартис АГ (CH) MICROEMULSION MEDICINAL FORMS OF VALSARTAN AND METHODS FOR PRODUCING THEM
WO2008076780A2 (en) * 2006-12-14 2008-06-26 Isp Investments Inc. Amorphous valsartan and the production thereof
WO2008084504A2 (en) * 2007-01-12 2008-07-17 Rubicon Research Private Limited Pharmaceutical compositions of angiotensin ii receptor blockers
RU2009141539A (en) * 2007-04-25 2011-05-27 Тева Фармасьютикал Индастриес Лтд. (Il) COMPLEX OF PHARMACEUTICAL FILLER
EP2167047A2 (en) * 2007-06-06 2010-03-31 Dexcel Ltd. Process for forming solid oral dosage forms of angiotensin ii receptor antagonists
RU2010104960A (en) * 2007-08-01 2011-09-10 Тева Фармасьютикал Индастриес Лтд. (Il) PHARMACEUTICAL COMPOSITION OF CANDESARTAN
JP2011500577A (en) * 2007-10-09 2011-01-06 ノバルティス アーゲー Pharmaceutical formulation of valsartan
AR068916A1 (en) * 2007-10-19 2009-12-16 Abbott Gmbh & Co Kg SOLID DISPERSION PRODUCT CONTAINING A N-ARIL UREA-BASED COMPOUND
JP5222550B2 (en) * 2007-12-27 2013-06-26 財團法人工業技術研究院 Sustained release composition and method for producing the same
WO2009084040A1 (en) * 2007-12-28 2009-07-09 Rubicon Research Private Limited Once a day formulation of angiotensin receptor blockers
CA2713581A1 (en) * 2008-02-28 2009-09-03 Novartis Ag Valsartan solid oral dosage forms and methods of making such formulations
KR20110015650A (en) * 2008-06-03 2011-02-16 노파르티스 아게 Pulsatile release of valsartan
PT2165702E (en) 2008-09-17 2012-02-07 Helm Ag Stable and readily dissolved compositions of candesartan cilexetil prepared with wet granulation
DE102008047910A1 (en) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tabletting excipient based on lactose and cellulose
EP2446879B1 (en) * 2009-06-25 2014-02-12 Jin Yang Pharm. Co., Ltd. Pharmaceutical composition containing carboxylosartan and a production method therefor
WO2011028016A2 (en) * 2009-09-04 2011-03-10 한올바이오파마주식회사 Pharmaceutical preparation comprising beta-adrenergic blockers and angiotensin ii receptor blockers
US9358204B2 (en) * 2012-02-08 2016-06-07 Supernus Pharmaceuticals, Inc. Formulations of viloxazine
WO2014088123A1 (en) * 2012-12-05 2014-06-12 Sawai Pharmaceutical Co., Ltd. Candesartan cilexetil-containing preparation
WO2014119667A1 (en) 2013-01-30 2014-08-07 沢井製薬株式会社 Pharmaceutical composition containing candesartan cilexetil
WO2016005994A2 (en) * 2014-07-06 2016-01-14 Gattefosse India Pvt. Ltd. Pharmaceutical composition comprising solid dispersion of bcs class ii drugs with gelucires
US9675585B1 (en) 2016-03-24 2017-06-13 Ezra Pharma Extended release pharmaceutical formulations
US9687475B1 (en) 2016-03-24 2017-06-27 Ezra Pharma Llc Extended release pharmaceutical formulations with controlled impurity levels
AU2018345647A1 (en) 2017-10-04 2020-04-16 Celgene Corporation Compositions and methods of use of cis-4-(2-{((3S,4R)-3-fluorooxan-4-yl) amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide
CN109350609A (en) * 2018-11-14 2019-02-19 常州大学 A kind of preparation of chitosan package zeins nanoparticle and the application for loading acacetin sodium salt
CN113933472B (en) * 2020-06-29 2024-07-09 武汉武药科技有限公司 Dissolution medium for determining dissolution rate of telmisartan solid preparation and application thereof
CN112516105A (en) * 2020-12-10 2021-03-19 成都恒瑞制药有限公司 Losartan potassium oral preparation and preparation method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2004105694A2 (en) * 2003-05-22 2004-12-09 Lipocine, Inc. Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
WO2005041929A1 (en) * 2003-11-03 2005-05-12 Lipocine, Inc Pharmaceutical compositions with synchronized solubilizer release
WO2005056607A1 (en) * 2003-12-12 2005-06-23 Belupo-Lijekovi I Kozmetika D.D. PROCESS FOR PRODUCTION OF INCLUSION COMPLEXES OF VALSARTAN WITH β-CYCLODEXTRIN

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
JP3751287B2 (en) * 2002-03-27 2006-03-01 バイエル薬品株式会社 Miniaturized nifedipine nucleated tablets
EP1575581A1 (en) * 2002-12-18 2005-09-21 Novartis AG Combinations of valsartan with cox-2 inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
WO2004105694A2 (en) * 2003-05-22 2004-12-09 Lipocine, Inc. Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
WO2005041929A1 (en) * 2003-11-03 2005-05-12 Lipocine, Inc Pharmaceutical compositions with synchronized solubilizer release
WO2005056607A1 (en) * 2003-12-12 2005-06-23 Belupo-Lijekovi I Kozmetika D.D. PROCESS FOR PRODUCTION OF INCLUSION COMPLEXES OF VALSARTAN WITH β-CYCLODEXTRIN

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FOGARI, R. ET AL: "Comparative efficacy of losartan and valsartan in mild-to-moderate hypertension: Results of 24-hour ambulatory blood pressure monitoring", CURRENT THERAPEUTIC RESEARCH, vol. 60, no. 4, April 1999 (1999-04-01), pages 195 - 206, XP002575013 *

Also Published As

Publication number Publication date
WO2006113631A3 (en) 2006-12-14
AU2006236497A1 (en) 2006-10-26
IL186721A0 (en) 2008-02-09
JP2008536929A (en) 2008-09-11
MX2007012947A (en) 2008-04-09
KR20080042039A (en) 2008-05-14
WO2006113631A2 (en) 2006-10-26
EP1877042A2 (en) 2008-01-16
CA2605183A1 (en) 2006-10-26

Similar Documents

Publication Publication Date Title
IL191572A0 (en) Pestcidal compositions
GB0503337D0 (en) Compositions
IL186721A0 (en) Bioenhanced compositions
EP1930012A4 (en) Cellooligosaccharide-containing composition
GB0526283D0 (en) Compositions
IL186093A0 (en) Lignan-containing compositions
GB0501192D0 (en) Stable prostaglandin-containing compositions
GB0501365D0 (en) Compositions
EP1865042A4 (en) Frost-preventive composition
GB0524128D0 (en) Compositions
GB0508250D0 (en) Composition
GB0506044D0 (en) Composition
EP1847249A4 (en) Hairdye composition
GB0502479D0 (en) Novel compositions
GB0507167D0 (en) Composition
GB0502475D0 (en) Novel compositions
ZA200709913B (en) Bioenhanced compositions
EP1947129A4 (en) Photoradial- and photocation-curable composition
EP1864573A4 (en) Agricultural-chemical composition
GB0525321D0 (en) Novel compositions
GB0526282D0 (en) Compositions
GB0502341D0 (en) Composition
GB0524803D0 (en) Novel compositions
GB0513641D0 (en) Anti-egeing composition
GB0501364D0 (en) Compositions

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20071116

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1117389

Country of ref document: HK

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/50 20060101ALI20110120BHEP

Ipc: A61K 9/20 20060101AFI20061113BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20110128

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110826

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1117389

Country of ref document: HK